This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Stocks Hitting New 52-Week Highs

Progencis Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Progencis Pharmaceuticals (PGNX - Get Report) is a biopharmaceutical company focusing on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. This stock is trading up 2.8% at $8.73 in recent trading after hitting a 52-week high of $9.12 earlier in the day.

Today's Range: $8.22-$9.12

52-Week Range: $4.50-$8.69

Volume: 621,000

Three-Month Average Volume: 163,611

Progenics Pharmaceuticals has a market cap of $296.43 million and an enterprise value of $208.65 million. The stock trades at a trailing price-to-earnings of 122.08. Its estimated growth rate for this year is 115.9% and for next year it's pegged at -129.4%. The current short interest as a percentage of the float for Genomic Health sits at 4.3%.

From a technical standpoint, PGNX recently gapped up and broke out above some near-term overhead resistance at $7.70 and $7.93 a share on monster volume. Volume on the breakout day hit over 2 million shares, which is well above its three-month average volume of just 163,611 shares.

The stock has now started to breakout again above $8.69 a share on strong volume. Market players should continue to look for long biases trades in PGNX as long as the stock can sustain a move and close above $8.69.
6 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ELN $0.00 0.00%
PETM $82.98 0.04%
AMGN $158.30 0.00%
HSTM $22.62 0.00%
PGNX $5.31 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs